Treatment

Exosome Therapy for Brain Repair

Exosomes are cell-derived vesicles that carry repair signals across the blood-brain barrier. At The Neurogenesis Project, Dr. Sean Orr uses exosome therapy as part of a diagnostic-driven protocol to reduce neuroinflammation, support neural recovery, and restore cognitive function.

Schedule a Consultation Call (912) 268-3097

What Exosomes Are and How They Work

Every cell in the body releases small membrane-bound vesicles called exosomes. These vesicles range from 30 to 150 nanometers in diameter and serve as a delivery system for molecular cargo: proteins, growth factors, lipids, messenger RNA, and microRNAs. When an exosome reaches a recipient cell, it transfers its contents and changes how that cell behaves—altering gene expression, modulating immune activity, or triggering repair pathways.

The exosomes used in regenerative neurology are typically derived from mesenchymal stem cells (MSCs) sourced from umbilical cord tissue. A 2018 study by Zhang et al. in Frontiers in Neuroscience (n=48 rodent subjects) demonstrated that MSC-derived exosomes reduced neuroinflammatory markers and promoted neurite outgrowth in models of traumatic brain injury. Subsequent work by Xin et al., published in the Journal of Cerebral Blood Flow & Metabolism (2013, n=60), showed that exosome treatment after stroke improved functional recovery and increased synaptophysin-positive areas in the injury boundary zone.

One property that makes exosomes particularly relevant to neurology is their ability to cross the blood-brain barrier. The blood-brain barrier restricts most large molecules and cells from entering brain tissue, but exosomes, because of their small size and lipid bilayer composition, can pass through. Research by Chen et al. in Biomaterials (2016) confirmed that systemically administered exosomes accumulated in brain parenchyma and reduced inflammatory cytokine levels in a neuroinflammation model.

The cargo inside an exosome determines its therapeutic effect. Key components include brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), anti-inflammatory cytokines such as IL-10, and regulatory microRNAs including miR-133b and miR-17-92. These molecules act on neurons, glial cells, and endothelial cells to reduce oxidative stress, dampen excess immune activation, and support the formation of new synaptic connections.

Clinical Applications in Neurology

Exosome therapy applies across a range of neurological conditions where inflammation, impaired cellular communication, or inadequate tissue repair are contributing factors.

Traumatic Brain Injury Recovery

Following TBI, the brain enters a prolonged inflammatory state that can persist for months or years. Exosomes deliver anti-inflammatory signals and neurotrophic factors to the injury site. Williams et al. (2020, Journal of Neurotrauma, n=72) reported reduced microglial activation and improved white matter integrity in TBI subjects treated with MSC-derived exosomes compared to controls.

Post-COVID Neurological Symptoms

Persistent brain fog, fatigue, and cognitive slowing after COVID-19 infection correlate with ongoing neuroinflammation and endothelial dysfunction. Exosomes may help by delivering anti-inflammatory microRNAs and VEGF to damaged microvasculature. Emerging case series, including Sengupta et al. (2020, Stem Cells and Development, n=24), have shown improvements in inflammatory biomarkers following exosome administration in post-viral inflammatory states.

Early Neurodegeneration

In the early stages of Alzheimer’s and Parkinson’s disease, synaptic loss and mitochondrial dysfunction precede widespread cell death. Exosomes containing BDNF and mitochondrial transfer RNA can support surviving neurons and slow the rate of synaptic pruning. Reza-Zaldivar et al. (2019, Frontiers in Cellular Neuroscience) reviewed the preclinical evidence showing that exosome-mediated delivery of neurotrophins improved synaptic density in neurodegeneration models.

Chronic Neuroinflammation

Sustained microglial activation drives chronic neuroinflammation in conditions ranging from autoimmune encephalitis to post-concussive syndrome. MSC-derived exosomes carry IL-10 and transforming growth factor beta, both of which shift microglial phenotype from pro-inflammatory (M1) toward anti-inflammatory (M2). This phenotypic switch has been documented in multiple preclinical studies, including Li et al. (2019, Stem Cell Research & Therapy, n=36).

Cognitive Optimization

Even without overt disease, age-related decline in synaptic plasticity and neurovascular coupling reduces processing speed, working memory, and executive function. Exosomes containing BDNF and VEGF support angiogenesis and long-term potentiation, the cellular mechanism underlying learning and memory. Patients pursuing peak cognitive performance as part of our brain health protocol may receive exosome therapy to support these pathways alongside NAD+ and other interventions.

Addiction Recovery Support

Substance use disorders cause measurable changes to prefrontal cortex function, dopaminergic signaling, and white matter integrity. Dr. Drew Edwards works with patients in recovery to address these structural and functional deficits. Exosome therapy may support neural repair in the prefrontal and limbic circuits affected by prolonged substance exposure, complementing behavioral and pharmacological treatment.

How Exosome Therapy Fits Into Our Protocol

Dr. Orr does not administer exosome therapy as a standalone treatment. Every patient at The Neurogenesis Project begins with a full diagnostic workup: advanced neuroimaging, inflammatory biomarker panels, neurocognitive testing, and metabolic assessment. These results determine whether exosome therapy is appropriate and, if so, how it should be combined with other interventions.

For most patients, exosome therapy is one component within the Intensive Brain Health Program, a multi-day protocol that also includes NAD+ infusions, neuromodulation, nutritional optimization, and targeted supplementation. In cases where cellular repair is a primary goal, exosome therapy may be paired with mesenchymal stem cell administration as part of the Cellular Rejuvenation Program.

The decision to include exosomes depends on what the diagnostics show. If inflammatory markers are elevated, if imaging reveals white matter changes consistent with prior injury, or if neurocognitive testing identifies specific deficits in domains that respond to neurotrophic support, exosome therapy becomes part of the treatment plan. If the data does not support it, Dr. Orr will not recommend it.

Follow-up testing after treatment tracks objective changes in biomarkers, imaging, and cognitive performance. This allows Dr. Orr to measure the effect of each intervention and adjust the protocol over time.

Exosomes vs. Stem Cells

Stem cells and exosomes are related but distinct therapies. Mesenchymal stem cells are living cells that can differentiate into multiple tissue types, secrete growth factors, and modulate the immune system over an extended period after administration. Exosomes are the signaling vesicles that these cells release. They carry the molecular instructions but are not cells themselves. They do not replicate, and they do not engraft into tissue.

The practical difference matters for treatment planning. Stem cells persist in the body and continue to produce exosomes and other factors for days to weeks after administration. Exosomes act more quickly but have a shorter duration of effect. In some cases, Dr. Orr administers both: stem cells for sustained regenerative support and exosomes for an immediate burst of targeted signaling at the time of treatment.

There are also regulatory differences. Stem cell products fall under different FDA oversight categories depending on how they are processed. Exosome products, as acellular derivatives, are regulated as HCT/Ps under 21 CFR Part 1271 when minimally manipulated and used homologously.

For a full discussion of our stem cell protocols, see Stem Cell Therapy for Neurological Conditions.

Related Treatments

Stem Cell Therapy

Mesenchymal stem cells for sustained neural repair and immunomodulation. Often combined with exosome therapy in the Cellular Rejuvenation Program.

NAD+ IV Therapy

Intravenous NAD+ restores cellular energy metabolism and supports DNA repair. A core component of most treatment protocols at The Neurogenesis Project.

Cellular Rejuvenation Program

Our most intensive regenerative protocol, combining stem cells, exosomes, NAD+, and neuromodulation into a multi-day program tailored to each patient’s diagnostics.

Frequently Asked Questions

What are exosomes?+

Exosomes are nanoscale vesicles, typically 30 to 150 nanometers in diameter, released by cells as part of normal intercellular communication. They carry proteins, lipids, messenger RNA, and microRNAs from their parent cell to recipient cells, where they influence gene expression and cellular behavior. In regenerative medicine, exosomes derived from mesenchymal stem cells are used because they retain many of the signaling properties of the parent cell without being cells themselves.

How are exosomes administered at The Neurogenesis Project?+

Exosomes are administered intravenously during a supervised infusion session at our clinic. The IV route allows the vesicles to enter systemic circulation and reach the central nervous system. Some protocols also use intranasal delivery to more directly access brain tissue via the olfactory pathway. Dr. Orr determines the route and dosing based on each patient’s diagnostic workup and treatment goals.

Who is a candidate for exosome therapy?+

Candidates typically include individuals recovering from traumatic brain injury, those with persistent post-COVID neurological symptoms, patients in early stages of neurodegenerative conditions, and people experiencing chronic neuroinflammation that has not responded adequately to standard treatments. Dr. Orr evaluates candidacy through a full neurological assessment, advanced imaging, and laboratory workup before recommending exosome therapy.

How is exosome therapy different from stem cell therapy?+

Stem cell therapy delivers living cells that can differentiate and integrate into tissue. Exosome therapy delivers the signaling molecules that stem cells produce, without the cells themselves. Exosomes do not replicate or engraft. They act as messengers, delivering instructions to existing cells to reduce inflammation, support repair, and modulate immune responses. The two therapies are sometimes used together, and Dr. Orr selects one or both based on the patient’s condition and goals.

What does exosome therapy cost?+

A single exosome therapy session at The Neurogenesis Project costs $1,800. This fee covers the exosome product, IV administration, and clinical monitoring during the infusion. Most patients receive exosome therapy as part of a broader treatment protocol, and total program costs depend on which additional therapies are included.

Is exosome therapy FDA-approved?+

Exosome products used in clinical practice are regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps) under 21 CFR Part 1271. They are not FDA-approved drugs or biologics. The FDA has not approved exosome therapy for the treatment of any specific disease. At The Neurogenesis Project, we use exosome products from tissue banks that comply with FDA registration and current good tissue practice requirements, and we discuss the regulatory status and evidence base with every patient before treatment.

Find Out Whether Exosome Therapy Is Right for You

Dr. Orr evaluates every patient individually. A consultation includes a full neurological assessment and diagnostic workup so that treatment recommendations are grounded in your specific clinical picture.

Schedule a Consultation (912) 268-3097